Investigational drug reduces number of lesions in patients with multiple sclerosis

   The investigational oral drug ONO-4641 has been shown to reduce the number of lesions in patients (N=407) with multiple sclerosis (MS), according to the results of a phase two trial.

   Researchers at the University of Colorado in Denver followed patients (N=407) randomly given placebo, 0.05 mg, 0.10 mg, or 0.15 mg of ONO-4641 once daily for 26 weeks. They were included in the study if they had two or more relapses in the two years prior to the study, one or more relapses within the year prior to the study, or one or more new MS-related brain lesions (Gd-enhancing lesions), detected on MRI within the three months prior to the study.

   The researchers found that patients taking 0.05, 0.10, or 0.15 mg of the study drug had 82%, 92%, and 77%, respectively, of fewer Gd-enhancing brain lesions compared with placebo.